Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(quinolin-8-yl)methanesulfonamide is a synthetic small molecule belonging to the sulfonamide class, characterized by a quinoline moiety linked to a methanesulfonamide group. It has been studied primarily as an experimental compound in medicinal chemistry and chemical biology. The compound exhibits potential antimicrobial activity and has been explored for its ability to act as a bidentate ligand, coordinating with metal ions via the sulfonamide nitrogen and quinoline nitrogen atoms. In pharmacophore libraries, it has shown promise in targeting enzymes such as Glyoxalase 1 (GLO1), suggesting possible roles in modulating metal-binding interactions relevant to oncology and antimicrobial research[3][6]. However, there are no approved indications or clinical trials beyond preclinical investigation[1][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(quinolin-8-yl)methanesulfonamide.